Application Notes

Cellastim S – Reconstitution Application Note

rHSA Reconstitution Video Protocol

AAV Production – How To Improve Transfection Efficiency and Titer Yield

Exbumin – Stabilizing Virus with Albumin to Improve Yield Application Note

OptiVERO – Formulation of a blood-free and chemically defined virus production media for VERO cells

Blog

Improvement of Vaccine Manufacturing Process with Use of Recombinant HSA Excipient

Recombinant Albumin for Stabilization of Live-Attenuated Viral Vaccines

Recombinant Virus Platforms are Out in Front in the Race to Develop Vaccines Against SARS-CoV-2 and COVID-19 Disease

Solving the Vaccine Supply Challenge

Journal Articles (DOI Links)

Utilization of Recombinant Albumins in the Expansion of Human T Lymphocytes

Accurate nanoelectrode recording of human pluripotent cell-derived cardiomyocytes for assaying drugs and modeling disease

Improvements in Viral Vector Manufacturing Process with Chemical Definition of Cell Culture Media & Excipients

Posters

Improving Vaccine Development, Performance, and Stability with Recombinant HSA Excipient

Product Brochures

2021 Product Catalog

SDS

Exbumin – Safety Data Sheet

Optibumin – Safety Data Sheet

Cellastim S – Safety Data Sheet

Use Guidelines

Cellastim S – Guidelines for Use

Exbumin – Guidelines for Use

Webinar

Accelerating Vaccine Development Through Use of Blood-Free Components

White Papers

Cellastim S – Recombinant Human Serum Albumin in the Generation of Functional Cardiomyocytes from Pluripotent Stem Cells

Emergence of Blood-Free Recombinant Human Albumin